Combined LDR Boost and HDR Whole Gland
common.study.values.description
“Combined LDR Boost and HDR Whole Gland”
This is a dose finding Phase I/II study of combined focused LDR brachytherapy boost with whole gland single fraction HDR for men with low and intermediate risk prostate cancer and Dominant Intraprostatic Lesion (DIL) visible on multi parametric MRI. Patients will receive 19 Gy HDR to the whole gland with concurrent LDR brachytherapy boost to the DIL, in a sequential dose escalation manner. Primary endpoints are early toxicity.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
Radiation - LDR/HDR
Focal LDR to dominant lesion with whole gland 19 Gy HDR
participant.views.study.view.additional
participant.views.study.view.scientific-title
Dominant Intraprostatic Lesion Boost With Focused LDR Brachytherapy (BT) Integrated to Whole Prostate HDR BT: Safety and Feasibility Analysis
common.study.values.clinical-trial-id
NCT03323879
participant.views.study.view.id
7ax3ne
